Please login to the form below
Rybelsus
This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.
Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial
Also within Novo’s roster is an oral formulation of semaglutide – marketed under the Rybelsus brand name – that is authorised for the treatment of type 2 diabetes.
Latest news
-
Novo Nordisk set to acquire Emisphere Technology for $1.8bn
Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide). ... Novo won US Food and Drug Administration (FDA) approval for
-
Lilly’s Trulicity scores CV reduction indication in the US
Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto Securities have suggested that demand for an oral alternative GLP-1 could make the drug a $5.4bn
-
New drugs drive Novo Nordisk despite insulin price pressures
Novo also reported sales of DKK50m for its recently launched oral semaglutide product Rybelsus in the quarter – the company has said it is encouraged by the early performance of the drug, ... The Rybelsus launch in the US is off to a good start, and
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide. ... In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved
-
Novo Nordisk gets MACE prevention claim for Ozempic in US
Otherwise, it is also conducting a dedicated cardiovascular outcomes trial for Rybelsus – SOUL – that is due to generate data in 2024. ... Some market predictors think Rybelsus could go even higher if the SOUL data is competitive.
More from news
Approximately 4 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
On our best behaviour
Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
-
Cortellis Drugs to Watch in 2020 report
7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- First trial of a vaccine against Alzheimer’s launches
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- AbbVie/Allergan merger faces renewed public opposition despite divestments
- AbbVie/Allergan's merger faces public opposition
- AstraZeneca officially opens new R&D facility in UK
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
